BINCHE PHARMA
ActiveSummary
The computed 12-month bankruptcy probability of BINCHE PHARMA is 2.1% (moderate). The 2025 annual accounts show equity of €97k and a net result of €-6k. Equity is growing by ~52.5% per year across the filed fiscal years. Its solvency ranks better than 17% of 10359 sector peers (fiscal year 2025). The company has been active since 2021 and the Belgian State Gazette contains no insolvency or warning signals.
Checked score
Score 2025
51
/ 100
Fair
The score weighs solvency, liquidity and profitability. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability68▼-5
Solvency31=
Growth52▼-26
Track record94
Bankruptcy probability, 12 months
2.1%
Moderate
0%0.5%1.5%4%10%≥ 25%
Credit up to €4.5k at 30 days acceptable
Liquidity short (current ratio 0.85 against 0.99 in 2024; short-term debt: 31.8% and cash: 7.7% of total assets), and 93.6% of the assets are financed with debt.
Credit check for your own amount and term
Signals
Five signals. The signal on the left, the evidence on the right.
+raises risk○neutral
raises risk · Limited track record
This company has not been active as long as an established one and statistically fails somewhat more often.
KBO · incorporation dateAge against the risk zone
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Sector 47
higher
← fewer bankruptcies
more bankruptcies →
raises risk · Weak solvency vs sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 17% of 10359 sector peers (2025).
NBB · sector comparisonPosition among 10359 sector peers
Solvency
better than 17%
← weakest
strongest →
neutral · Filed after the deadline
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 27-08-2026, 27 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
NBB · 4 filingsDeviation from the deadline
2025
27 d late
2024
on the day
2023
30 d late
2022
151 d late
← before the deadline
after the deadline →
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
24-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, abbreviated schema
Turnover
Not included in this filing
EBIT margin
Not included in this filing
Net result
€-6k
2024 · €50k
2022: €-5k
2023: €48k
2024: €50k
2022 → 2025
Working capital
€-72k▼ 2,352%
2024 · €-3k
2022: €-7k
2023: €-5k
2024: €-3k
2022 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line2022202320242025Trend
Equity€5k-€52k▲ 1,017%€102k▲ 95.8%€97k▼ 5.4%
Operating result€108k-€100k▼ 7.7%€107k▲ 6.8%€34k▼ 68.3%
Net result€-5k-€48k€50k▲ 5.3%€-6k
Result per fiscal year
Operating resultNet result
The operating result falls in 2025; 2025 is 68% below 2024 and is the lowest result in the available series.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €1.51M
Fixed assets
€1.10M ▼ 7.2%
Current assets
€406k ▼ 10.3%
Equity and liabilities €1.51M
Equity
€97k ▼ 5.4%
Debt
€1.41M ▼ 8.2%
Debt's share of the balance-sheet total falls from 93.8% to 93.6%. Equity and debt are lower.
Key figures and ratios
EBITDA
€119k▼
2024 · €194k
Cash flow
€79k▼
2024 · €138k
Current ratio
0.85▼
2024 · 0.99
Quick ratio
0.48▼
2024 · 0.63
Debt to equity
14.56▼
2024 · 15.01
ROE
-5.7%▼
2024 · 48.9%
ROA
-0.4%▼
2024 · 3.1%
Interest coverage
6.92▼
2024 · 10.24
Debt ≤ 1 year
€478k▲
2024 · €456k
Debt > 1 year
€930k▼
2024 · €1.07M
Income taxes
€23k▼
2024 · €39k
Staff costs
€371k▲
2024 · €361k
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Filed annual accounts As filed with the NBB · 2025 against 2024 · 52 lines
Balance sheet
Code20242025
Assets
Total assets20/58€1.64M€1.51M▼
Fixed assets21/28€1.18M€1.10M▼
Intangible fixed assets21€1.12M€1.05M▼
Tangible fixed assets22/27€64k€47k▼
Land and buildings22€60k€45k▼
Plant, machinery and equipment23€3k€2k▼
Furniture and vehicles24€1k-
Financial fixed assets28€73€73=
Current assets29/58€453k€406k▼
Stocks and contracts in progress3€166k€174k▲
Stocks30/36€166k€174k▲
Amounts receivable within one year40/41€89k€111k▲
Trade receivables40€88k€102k▲
Other amounts receivable41€763€8k▲
Cash at bank and in hand54/58€194k€116k▼
Deferred charges and accrued income490/1€4k€5k▲
Equity and liabilities
Total equity and liabilities10/49€1.64M€1.51M▼
Equity10/15€102k€97k▼
Contributions10/11€10k€10k=
Reserves13€92k€87k▼
Distributable reserves133€92k€87k▼
Amounts payable17/49€1.53M€1.41M▼
Amounts payable after more than one year17€1.07M€930k▼
Financial debts170/4€1.07M€930k▼
Amounts payable within one year42/48€456k€478k▲
Current portion of amounts payable after more than one year42€136k€147k▲
Trade debts44€102k€92k▼
Suppliers440/4€98k€92k▼
Bills of exchange payable441€3k-
Taxes, remuneration and social security45€120k€91k▼
Taxes450/3€78k€91k▲
Remuneration and social security454/9€42k-
Other amounts payable47/48€98k€147k▲
Accrued charges and deferred income492/3€12k€1k▼
Income statement
Code20242025
Remuneration, social security and pensions62€361k€371k▲
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€88k€85k▼
Other operating charges640/8€1k€386▼
Gross operating margin9900€556k€490k▼
Operating profit (loss)9901€107k€34k▼
Financial income75/76B€959€920▼
Recurring financial income75€959€920▼
Financial charges65/66B€19k€17k▼
Recurring financial charges65€19k€17k▼
Profit (loss) for the period before taxes9903€89k€18k▼
Income taxes67/77€39k€23k▼
Profit (loss) for the period9904€50k€-6k▼
Profit (loss) for the period to be appropriated9905€50k€-6k▼
Appropriation of the result
Profit (loss) to be appropriated9906€50k€-6k▼
Transfer from equity791/2-€6k
Transfer to equity691/2€50k-
To other reserves6921€50k-
Social balance
Average headcount (FTE)90875.95.4▼
The notes to these accounts (11 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
27-08
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema · 27 days late
2025
31-12
Financial
Weakest financial yearnet €-6k ▼111%
Net result drops to €-6k, the lowest in the series.
31-07
NBB filing
Annual accounts filed
fiscal year 2024 · full schema
2024
31-12
Financial
Highest result since 2022net €50k ▲5.3%
Net result €50k, the highest in the series.
31-12
Financial
Equity above €100kEq €102k ▲95.8%
2 profitable years in a row build equity to €102k.
30-08
NBB filing
Annual accounts filed
fiscal year 2023 · full schema · 30 days late
2023
31-12
Financial
Back to profitnet €48k
Net result €48k after one loss-making year.
29-12
NBB filing
Annual accounts filed
fiscal year 2022 · full schema · 151 days late
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
6 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Binche · 1 establishment unit since 2021
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Rue de Robiano(BIN) 667130 BincheGround area
345 m²
Building footprint
191 m²
Volume, LiDAR
2,374 m³
2 parcels, Wallonia · tallest building 15.7 m, ±4 floors. Linked by address, not a title deed.
1 establishment unit
BINCHE PHARMA
since 20212.317.920.512
2 parcels
Wallonia
2
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 56011B0433/00M000 | Wallonia | 206 m² | 1 · 126 m² | 15.7 m · 4 fl. |
| 56011C0030/00C016 | Wallonia | 139 m² | 1 · 65 m² | 13.3 m · 4 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1 · via establishment units: 1
2 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Recognitions · licences · registrations
Food safety, FASFC
1 siteBinche2.317.920.512
Similar companies · same sector, comparable size
Pharmacie Valkenborgh
BE 0422.140.535
Seraing · Eq €96,746
PARAPHARMACIE DISCOUNT BRAINE L'ALLEUD
BE 0712.664.443
Braine-l'Alleud · Eq €96,682
APOTHEEK VOSSELARE
BE 0698.795.621
Deinze · Eq €96,874
FarmaST
BE 0799.144.002
Zonhoven · Eq €96,555
PHARDEC
BE 0428.399.807
Koekelberg · Eq €97,054
Of 5,220 companies in sector 47730 we hold annual accounts for 3,861. 3,404 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded07-05-2021
Fiscal year end31-12
Activities, NACEBEL 2025
47730Retail sale of pharmaceutical products
Sources
Crossroads Bank for EnterprisesNational Bank · 4 filingsAddress and cadastre registers
Scores and ratios are computed by Checked and are not a credit decision.